Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the ...

Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to new ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

FROM sulphur burps to diarrhoea, we’re all familiar with the brutal side effects of fat jabs – but have you heard of ‘Ozempic ...